Please note that this meeting will take place as an in-person event in Portland and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program is subject to change. 

[R] – Remote Presentation
*-Short talk selected from proffered abstracts

saturday, october 1, 2022

Welcome and Opening Keynote Address

sunday, october 2, 2022

Special Session: Moving The Needle
Plenary Session 1: Risk Prediction of Colorectal Cancer Incidence and Surveillance
Plenary Session 2: Advances in 3D Models, Cultures, Organoids, and PDXs
Plenary Session 3: Early Onset Colorectal Cancer

monday, october 3, 2022

Plenary Session 4: Insights and Therapies for Colorectal Cancer Immune Microenvironment
Keynote Address
Plenary Session 5:  Microbiome
Plenary Session 6: Novel Therapeutics in Metastatic Colorectal Cancer

Tuesday, october 4, 2022

Plenary Session 7: Novel Insights into Pre-malignant Tumors
Plenary Session 8: Liquid Biopsies

saturday, october 1, 2022

Welcome and Opening Keynote ADDRESS
6–7 p.m.

Welcome from conference cochairs

Introduction of opening keynote speaker

Title to be announced
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York

Opening Reception
7-9 p.m.    

sunday, OCTOBER 2, 2022

continental breakfast
7-8 A.M.

special session: moving the needle
session chair: Scott kopetz, the university of texas md anderson cancer center, houston, texas
8-9:30 a.m.

Moving the needle by learning from the patient
Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, Texas

ctDNA Guiding adjuvant treatment in early stage colon cancer: Are we moving the needle?
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia [R]

Moving the needle: It is time for universal germline and somatic genetic testing in all colorectal cancer patients
Richard M. Goldberg, West Virginia University Cancer Institute, Morgantown, West Virginia

Break
9:30-10 a.m.

Plenary Session 1: Risk prediction of colorectal cancer incidence and surveillance
session chair: jiyoung ahn, new york university langone health, new york, new york
10 a.m.–12 P.m.

Risk prediction in colorectal cancer screening: Reflections on the current status
Robert E. Schoen, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

The effect of ancestry and the genomics of colorectal cancer: Implications on incidence and outcomes
Parvathi A. Myer, Albert Einstein College of Medicine, Bronx, New York

Time to extend screening colonoscopy intervals? If so, by how much and for whom? Findings at 120,000 repeat screening colonoscopies conducted 10 or more years after a negative screening colonoscopy
Hermann Brenner, German Cancer Research Center, Heidelberg, Germany [R]

The use of risk prediction for patients with abnormal fecal testing (FIT) to prioritize patient navigation*
Amanda F. Petrik, Kaiser Permanente Center for Health Research, Portland, Oregon

Development and validation of a risk prediction model for post-polypectomy colorectal cancer in 4 prospective US cohorts*
Mingyang Song, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Lunch (on own)
12-2 p.m.

Plenary Session 2: advances in 3d models, cultures, organoids, and pdxs
session chair: Nicholas c. zachos, vanderbilt university medical center, nashville, tennessee
2-4 p.m.

Modeling immune-epithelial interactions in health and disease using human intestinal enteroid co-cultures  
Nicholas C. Zachos, Vanderbilt University Medical Center, Nashville, Tennessee

Tumor organoids of multi-metastatic colorectal cancer: From research tools to treatment decision tools
Anita Sveen, Oslo University Hospital, Oslo, Norway

Patient derived organoids in precision oncology
Nicola Valeri, The Institute of Cancer Research, London, England, United Kingdom

Overexpression of the small GTPase Rab27B promotes tumor growth by regulating autophagy flux in colorectal cancer*
Dan A. Dixon, University of Kansas, Lawrence, Kansas

In vitro and in vivo CRISPR screens in colorectal cancer organoids identify suppressors of metastasis*
Zvi Cramer, University of Pennsylvania, Philadelphia, Pennsylvania

Break
4-4:30 p.m.                          

Plenary session 3: early onset colorectal cancer
session chair: yin cao, washington university in st. louis, st. louis, missouri
4:30-6:15 p.m.

Young onset colorectal cancer: Challenges and opportunities
Yi-Qian Nancy You, The University of Texas MD Anderson Cancer Center, Houston, Texas

Risk factors for early-onset colorectal cancer
Richard B. Hayes, New York University Langone Health, New York, New York

Early-onset colorectal cancer: Emerging risk factors and early detection
Yin Cao, Washington University in St. Louis, St. Louis, Missouri

Outcomes in colitis-associated metastatic colorectal cancer and intersection with early-onset and signet ring cell carcinoma*
Oscar E. Villarreal, UT Health Science Center at Houston, Houston, Texas

poster session a / reception
6:15-8:15 p.m.

monday, october 3, 2022

Continental breakfast
7-8 A.M.

Plenary Session 4: insights and therapies for colorectal cancer immune microenvironment
session chair: ronald a. depinho, the university of texas md anderson cancer center, houston, texas
8-10 a.m.

Synthetic essentiality identifies TDO2 as a key target in APC-deficient CRC
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, Texas

Combined single cell atlasing and organoid modeling reveal progressive plasticity during human colorectal cancer metastasis
Karuna Ganesh, Memorial Sloan Kettering Cancer Center, New York, New York

Stem cells, therapy resistance and metastasis in colorectal cancer
Eduard Batlle, Institute for Research in Biomedicine, Barcelona, Spain [R]

Impact of heterogeneity for mismatch repair activity on colon tumor development and therapeutic response*
Santina Snow, University of Wisconsin-Madison, Madison, Wisconsin

Intestinal intraepithelial T cells limit colorectal cancer progression*
Sonia Ghilas, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia

Break
10–10:30 a.m.

keynote address
10:30-11:20 A.m.

Introduction of keynote speaker
Jiyoung Ahn, New York University Langone Health, New York, New York

Microbiota drivers of colorectal cancer and their translation to prevention
Cynthia L. Sears, Johns Hopkins University, Baltimore, Maryland

lunch (on own)
11:20 a.m.–1 p.m.

Plenary Session 5: microbiome
session chair: shuji ogino, brigham and women’s hospital, harvard medical school, harvard t.h. chan school of public health, boston, massachusetts
1-2:45 p.m.

Microbiome and intestinal barriers in colon cancer
Jun Sun, University of Illinois Cancer Center, Chicago, Illinois

Molecular pathological epidemiology of tumor microbiota and immunity can give etiologic insights
Shuji Ogino, Brigham and Women’s Hospital, Harvard Medical School, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

The gut microbiome in colorectal cancer
Chloe E. Atreya, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Evaluation of intra-tumoral pathogenic bacteria pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum in 3695 colorectal cancer cases*
Meredith A. J. Hullar, Fred Hutchinson Cancer Research Center, Seattle, Washington

Break
2:45–3:15 p.m.

Plenary Session 6: novel therapeutics in metastatic colorectal cancer
session chair: ryan b. corcoran, massachusetts general hospital, harvard medical school, boston, massachusetts
3:15-5:15 p.m.

Targeting BRAF and KRAS mutated colorectal cancer
Ryan B. Corcoran, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Drivers of the drug tolerant persister state in colorectal cancer
Catherine A. O’Brien, University of Toronto, Toronto, Ontario, Canada

Targeting Her2 amplification in colorectal cancer 
Andrea Cercek, Memorial Sloan Kettering Cancer Center, New York, New York

RNF43 G659fs is an oncogenic and immune-modulating colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition*
Marios Giannakis, Dana-Farber Cancer Institute, Boston, Massachusetts

Inhibition of HGF maturation overcomes cetuximab resistance in colorectal cancer*
Bhuminder Singh, Vanderbilt University Medical Center, Nashville, Tennessee

poster session b / reception
5:15-7:15 p.m.

Tuesday, october 4

continental breakfast
7-8 A.M.

plenary session 7: novel insights into pre-malignant tumors
session chair: eduardo vilar-sanchez, the university of texas md anderson cancer center, houston, texas
8-10 A.M.

Multi-omic and single cell atlases of colorectal cancer pre-malignancy
Christina Curtis, Stanford University, Stanford, California

Stem and metaplastic cell states and their influences on the tumor immune microenvironment in colonic pre-cancerous lesions
Ken S. Lau, Vanderbilt University, Nashville, Tennessee

Novel insights into colorectal pre-cancers from hereditary cancer syndromes: From omics to interception
Eduardo Vilar-Sanchez, The University of Texas MD Anderson Cancer Center, Houston, Texas

Histone demethylase KDM5D drives sex-specific differences in colorectal cancer*
Jiexi Li, The University of Texas MD Anderson Cancer Center, Houston, Texas

Aberrant cell state plasticity mediates colorectal cancer initiation*
Nilay S. Sethi, Dana-Farber Cancer Institute, Boston, Massachusetts

break
10-10:30 A.M.

plenary session 8: liquid biopsies
session chair: robert j. coffey, vanderbilt university medical center, nashville, tennessee
10:30 a.m.-12:15 P.M.

Recent advances in the study of extracellular vesicles and nanoparticles in colorectal cancer
Robert J. Coffey, Vanderbilt University Medical Center, Nashville, Tennessee

Circulating tumor DNA in the management for colorectal cancer: Are we there yet?
Van Karlyle Morris, The University of Texas MD Anderson Cancer Center, Houston, Texas

Noncoding RNAs and DNA methylation alterations as liquid biopsy biomarkers in colorectal cancer
Ajay Goel, City of Hope Comprehensive Cancer Center, Duarte, California

Transcriptomic profiling of liquid biopsy in colorectal cancer*
Vahid Bahrambeigi, The University of Texas MD Anderson Cancer Center, Houston, Texas

closing remarks and departure
12:15 P.M.

Closing remarks
Robert J. Coffey, Vanderbilt University Medical Center, Nashville, Tennessee

Times may change slightly as the program develops with the inclusion of short talks from proffered abstracts.